Gilead Sciences Inc. has described GTPase KRAS inhibitors, particularly wild-type KRAS, KRAS (G12C mutant), KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors, found to be potentially useful for the treatment of cancer.